AMARIN PHARMS
PharmaAMARIN PHARMS is a pharmaceutical company focused on Cardiovascular, Metabolic. Key products include VASCEPA.
AMARIN PHARMS's Key Drugs
AMARIN PHARMS's core commercial portfolio centers on VASCEPA, spanning Cardiovascular and Metabolic — its most strategically important drugs approved in the last 15 years.
AMARIN PHARMS's Recent FDA Approvals
New NDA/BLA approvals for AMARIN PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
AMARIN PHARMS's Therapeutic Areas
AMARIN PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AMARIN PHARMS's Top Competitors
AMARIN PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AMARIN PHARMS Pipeline Snapshot
Active clinical trials for AMARIN PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VASCEPA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1974-05-15
- Latest
- 2019-12-13
- Applications
- 2